RenalSense's core product is the Clarity RMS, a continuous, automatic urine-flow monitoring system that provides real-time renal diagnostics. The Clarity RMS has FDA clearance and CE certification and is installed in tens of general and cardiovascular operating rooms, ICUs, transplant and COVID-19 units in leading medical centers across the US, Europe and Israel. The company sells through distribution partners including Fresenius Medical Care (Europe), Medline (North America), and Gloryway (China), and has added distributors in eastern Europe, Israel, and Taiwan (PAHSCO). RenalSense is pursuing expanded clinical validation beyond the ICU into cardiology and anesthesia while developing next-generation sensor-based products to deliver additional diagnostic parameters for renal and other vital organ function. Future products are intended for use beyond the critical-care setting. The company raised $14M in a Series A to bolster global commercialization, expand clinical validation, and advance next-generation product development.

Total raised

$14M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2021